Dr. Varun Sibal
MBBS (LTMMC), DNB (General Medicine),
DNB, (Cardiology),
Chief Interventional Cardiologist

A study involving 305 patients with heart failure (HF) with reduced ejection fraction found that 49.2% received two current recommended drugs at discharge. Among these, 93.4% received β-blockers, 68.2% received renin-angiotensin system inhibitors, 32.5% prescribed mineralocorticoid receptor antagonists, and 71.1% could prescribe sodium-glucose cotransporter 2 inhibitors. The study also found that 46.2% could receive the four foundational drugs at discharge. Renal dysfunction was associated with fewer foundational drugs prescribed. After adjustment of age and renal function, it was found that ≥ 2 drugs use was associated with reduced risk of rehospitalization during 30 days after discharge. The study concludes that a quadruple therapy could be directly implementable at discharge, potentially providing prognostic advantages, but renal dysfunction was the main prevalent condition limiting this approach. The study stated that more data will be required on the simultaneous start of four pharmacological pillars at discharge after a decompensation event.

Click Here to view the article:

Journal of the American Heart Association